These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 31263891)
41. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults. Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172 [TBL] [Abstract][Full Text] [Related]
42. Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United States. Havers FP; Cho BH; Walker JW; Hariri S Vaccine; 2020 Jan; 38(2):380-387. PubMed ID: 31676198 [TBL] [Abstract][Full Text] [Related]
43. Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women. Wanlapakorn N; Maertens K; Chaithongwongwatthana S; Srimuan D; Suratannon N; Vongpunsawad S; Tran TMP; Hens N; Van Damme P; Locht C; Poovorawan Y; Leuridan E Vaccine; 2018 Mar; 36(11):1453-1459. PubMed ID: 29426663 [TBL] [Abstract][Full Text] [Related]
44. Vaccination coverage rates for Diphtheria, Tetanus, Poliomyelitis and Pertussis booster vaccination in France between 2013 and 2017: Learnings from an analysis of National Health System Real-World Data. Marchal C; Belhassen M; Guiso N; Jacoud F; Van Ganse E; Le Pannerer M; Cohen R; Verdier R; Uhart M Vaccine; 2021 Jan; 39(3):505-511. PubMed ID: 33357956 [TBL] [Abstract][Full Text] [Related]
45. Knowledge, attitudes, beliefs and practices of obstetrics-gynecologists on seasonal influenza and pertussis immunizations in pregnant women: preliminary results from North-Western Italy. Ricco' M; Vezzosi L; Gualerzi G; Balzarini F; Capozzi VA; Volpi L Minerva Ginecol; 2019 Aug; 71(4):288-297. PubMed ID: 30938116 [TBL] [Abstract][Full Text] [Related]
46. A quality improvement initiative to increase Tdap (tetanus, diphtheria, acellular pertussis) vaccination coverage among direct health care providers at a children's hospital. Jiang C; Whitmore-Sisco L; Gaur AH; Adderson EE; Vaccine; 2018 Jan; 36(2):214-219. PubMed ID: 29217370 [TBL] [Abstract][Full Text] [Related]
47. An observational study of antibody responses to a primary or subsequent pertussis booster vaccination in Australian healthcare workers. McAlister SM; van den Biggelaar AHJ; Woodman TL; Hutton H; Thornton RB; Richmond PC Vaccine; 2021 Mar; 39(11):1642-1651. PubMed ID: 33589299 [TBL] [Abstract][Full Text] [Related]
48. Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults. Weston WM; Chandrashekar V; Friedland LR; Howe B Hum Vaccin; 2009 Dec; 5(12):858-66. PubMed ID: 19838080 [TBL] [Abstract][Full Text] [Related]
49. Seroprevalence of antibodies against diphtheria, tetanus, and pertussis among healthy Thai adolescents. Hanvatananukul P; Prasarakee C; Sarachai S; Aurpibul L; Sintupat K; Khampan R; Saheng J; Sudjaritruk T Int J Infect Dis; 2020 Jul; 96():422-430. PubMed ID: 32387447 [TBL] [Abstract][Full Text] [Related]
50. Lower Sustained Diphtheria and Pertussis Antibody Concentrations in Inflammatory Bowel Disease Patients. Caldera F; Saha S; Wald A; Garmoe CA; McCrone S; Megna B; Ley D; Reichelderfer M; Hayney MS Dig Dis Sci; 2018 Jun; 63(6):1532-1540. PubMed ID: 29594970 [TBL] [Abstract][Full Text] [Related]
51. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations. Bechini A; Tiscione E; Boccalini S; Levi M; Bonanni P Vaccine; 2012 Jul; 30(35):5179-90. PubMed ID: 22709953 [TBL] [Abstract][Full Text] [Related]
52. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. Blatter M; Friedland LR; Weston WM; Li P; Howe B Vaccine; 2009 Jan; 27(5):765-72. PubMed ID: 19041352 [TBL] [Abstract][Full Text] [Related]
53. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial. Zimmermann U; Gavazzi G; Richard P; Eymin C; Soubeyrand B; Baudin M Vaccine; 2013 Mar; 31(11):1496-502. PubMed ID: 23313654 [TBL] [Abstract][Full Text] [Related]
54. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Healy CM; Rench MA; Baker CJ Clin Infect Dis; 2013 Feb; 56(4):539-44. PubMed ID: 23097585 [TBL] [Abstract][Full Text] [Related]
55. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults. Leroux-Roels G; Lattanzi M; Solis CD; Contorni M; Costantini M; Moraschini L; Bardelli M; Bertholet S; Borgogni E; Buricchi F; Cantisani R; Faenzi E; Finco O; Leuzzi R; Pizza M; Rosa D; Schiavetti F; Seubert A; Spensieri F; Volpini G; Zedda L; Giudice GD; Galgani I Hum Vaccin Immunother; 2018 Jan; 14(1):45-58. PubMed ID: 29172945 [TBL] [Abstract][Full Text] [Related]
56. Robust Humoral and Cellular Immune Responses to Pertussis in Adults After a First Acellular Booster Vaccination. van der Lee S; van Rooijen DM; de Zeeuw-Brouwer ML; Bogaard MJM; van Gageldonk PGM; Marinovic AB; Sanders EAM; Berbers GAM; Buisman AM Front Immunol; 2018; 9():681. PubMed ID: 29670634 [TBL] [Abstract][Full Text] [Related]
57. Low seroprevalence of diphtheria, tetanus and pertussis in ambulatory adult patients: the need for lifelong vaccination. Tanriover MD; Soyler C; Ascioglu S; Cankurtaran M; Unal S Eur J Intern Med; 2014 Jul; 25(6):528-32. PubMed ID: 24814432 [TBL] [Abstract][Full Text] [Related]
58. Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial. Perrett KP; Halperin SA; Nolan T; Carmona Martínez A; Martinón-Torres F; García-Sicilia J; Virta M; Vanderkooi OG; Zuccotti GV; Manzoni P; Kostanyan L; Meyer N; Ceregido MA; Cheuvart B; Kuriyakose SO; Stranak Z; Merino Arribas JM; Cilleruelo Ortega MJ; Miranda-Valdivieso M; Arias Novas B; Ramos Amador JT; Omeñaca F; Baca M; Marchisio PG; Mesaros N Vaccine; 2020 Feb; 38(8):2105-2114. PubMed ID: 31776027 [TBL] [Abstract][Full Text] [Related]
59. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526 [TBL] [Abstract][Full Text] [Related]
60. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine. Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]